Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

548.05
+7.791.44%
Post-market: 548.050.00000.00%19:52 EDT
Volume:1.07M
Turnover:589.66M
Market Cap:139.05B
PE:31.90
High:555.32
Open:545.10
Low:540.70
Close:540.26
52wk High:555.32
52wk Low:374.17
Shares:253.72M
Float Shares:253.72M
Volume Ratio:0.86
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):17.18
EPS(LYR):15.32
ROE:23.54%
ROA:11.93%
PB:6.87
PE(LYR):35.77

Loading ...

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity

TIPRANKS
·
Jul 22

Vertex Facing Uncertain Growth Path Amid AI Fears, Morgan Stanley Says

MT Newswires Live
·
Jul 21

Morgan Stanley Downgrades Vertex to Equalweight From Overweight, Cuts Price Target to $15 From $19

MT Newswires Live
·
Jul 21

Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 21

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating

MT Newswires Live
·
Jul 20

Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 17

Vertex’s VX-581 Dose Escalation Trial: A Fresh Signal on Cystic Fibrosis Pipeline Strength

TIPRANKS
·
Jul 17

Vertex Pharmaceuticals BDR Program Executes 8-for-1 Stock Split in Brazil on July 27

Reuters
·
Jul 16

Vertex Pharmaceuticals Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since August 2021

Dow Jones
·
Jul 15

After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?

TIPRANKS
·
Jul 15

Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal

Simply Wall St.
·
Jul 15

Vertex Minerals lifts gold sales and advances mechanised mining at Reward

TIPRANKS
·
Jul 14

Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 14

Vertex Pharmaceuticals is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 14

UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating

MT Newswires Live
·
Jul 13

BMO Capital Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jul 13

Vertex Pharmaceuticals Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Jul 11

Crinetics Pharmaceuticals Announces Merger Agreement With Vertex

TIPRANKS
·
Jul 11

Vertex: Buy Rating Reaffirmed as Crinetics Deal Broadens Revenue Base; $575 Price Target Maintained

TIPRANKS
·
Jul 10

RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570

MT Newswires Live
·
Jul 10